Connect with us

US Futures, European Markets Rise After China’s First Rate Cut In 2 Years

US Futures, European Markets Rise After China’s First Rate Cut In 2 Years

US equity futures, European bourses and Asian markets were all broadly higher after China unexpectedly cut official policy rates for the first time since 2020…

Published

on

US Futures, European Markets Rise After China's First Rate Cut In 2 Years

US equity futures, European bourses and Asian markets were all broadly higher after China unexpectedly cut official policy rates for the first time since 2020...

... to counter an economic slowdown. A real-estate slump and partial Covid shutdowns are among the challenges for the world’s second-largest economy. The move contrasts with the shift toward tighter monetary policy in the U.S. and elsewhere to contain price pressures.

“The PBOC really has started the New Year in a different position to, let’s say, other global banks and we do expect to see further easing or supportive measures, both monetary-wise as well as from a fiscal stance,” Catherine Yeung, investment director at Fidelity International, said on Bloomberg Television. The Chinese move has prompted speculation that the current round of global central bank tightening will be short lived, which will be good news for high-duration tech stocks.

While the US is closed for MLK Day, US equity futures reversed earlier losses and traded near session highs, up 8 points or 0.2% to 4,662, as the tri-state area found itself covered under several inches of snow.

Europe’s Stoxx 600 Index and U.S. futures rose, while Asian shares closed modestly in the red. The dollar and oil were little changed. 

Even thought cash bond markets are closed, Treasury futs suggested yields had risen above 1.80% to a new multi year high, after yields tumbled Friday on concerns about more hawkish Federal Reserve policy to fight inflation. JPMorgan Chief Executive Officer Jamie Dimon, whose blank plunged after reporting disappointing trading revenues and surging expenses, said Friday the central bank could raise rates as many as seven times and traders are reconsidering an earlier kickoff for the first European Central Bank rate increase in more than a decade. Jamie Dimon will, of course, be dead wrong as he has been wrong about bitcoin.

Despite today's rise in futures, sentiment remains subdued and rallies are sold. The advance of the omicron virus strain, the start of the earnings season and a boom in mergers and acquisitions are also coloring sentiment. Investors are looking for signs that companies can sustain profit growth despite rising risks.

Meanwhile as part of its weekly pep talk (last week, JPM's Marko Kolanovic said it was time to buy the dip, the second week in a row the bank urged clients to do just that), JPMorgan said global company earnings will defy doomsayers and skeptics once again this season and surprise to the upside - a view at odds with recent warnings that inflation, rising rates, supply chain bottlenecks and slowing economic growth will curb companies’ prospects following last year’s blockbuster earnings growth.

Ironically, it was JPMorgan's earnings that sent the Dow sliding on Friday: Wall Street banks kicked off the earnings season with mixed results last week, disappointing investors and tamping down some profit expectations for this year.

“Given the record inflation backdrop and historically tight labor market, investor focus is on margins -- demonstrating pricing power, passing on rising costs to the customer,” Julian Emanuel, chief equity and quantitative strategist at Evercore ISI, wrote in a note.

European equities returning toward session highs after initially fading opening gains in a choppy start to the week. Euro Stoxx 50 gains as much as 0.7%. FTSE 100 and IBEX avoid the early fade seen in other equity indexes. Media, consumer products, tech and miners are the strongest sectors.  Among individual movers on Monday, Unilever Plc shares fell more than 7%, while GlaxoSmithKline Plc rose, as the consumer-products company considers making a higher offer for Glaxo’s consumer unit. Equipment maker BE Semiconductor rose to the highest since the stock’s 1995 listing after Oddo and Deutsche Bank boosted their price targets. In corporate developments, Credit Suisse Group AG’s Chairman Antonio Horta-Osorio was ousted for breaching Covid quarantine rules, throwing the Swiss financial giant into fresh turmoil as it struggles to emerge from a series of scandals.

Here are some of the biggest European movers today:

  • Stadler Rail surges as much as 8%, their best day since March 2020, following a contract win. The announcement of the company’s largest-ever contract marks “another major success,” Vontobel says.
  • Equipment maker BE Semiconductor rises as much as 6.3% to EU88.34 in Amsterdam trading, hitting the highest since the stock’s 1995 listing, after Oddo and Deutsche Bank boosted their price targets.
  • Siltronic declines as much as 11% after the company cast doubt on the planned $5.3b takeover by Taiwan’s GlobalWafers, saying the German Economy Ministry’s feedback so far was opaque and offered no clear resolution on how to win approval for the deal.
  • Ageas falls as much as 12%, the most since April 2020, after Belgium’s Federal Holding and Investment Company (FPIM) acquired a 6.3% stake in the reported takeover target.
  • Darktrace drops as much as 8.1% after the Telegraph reported Shadowfall is shorting the cybersecurity software firm.
  • Maersk slides as much as 6%, adding to Friday’s 4.4% tumble, after Nordea downgraded the Danish shipping firm to hold from buy, saying the exceptional demand situation will normalize in 2023.
  • Credit Suisse falls as much as 2.2% in Zurich after the Swiss bank ousted its chairman, leaving a number of analysts questioning the bank’s leadership.

Earlier in the session, Asian stocks fell as China’s economic data showed a slowdown in growth during the last quarter, with the nation’s central bank cutting a key interest rate for the first time in almost two years. The MSCI Asia Pacific Index dropped as much as 0.4%, slipping for a third session amid a slump in financials and materials. Mainland China’s CSI 300 Index closed up less than 1% after the People’s Bank of China cut two policy interest rates. China’s economy grew 4% in the final quarter of 2021 from a year earlier, a pace slower than during the previous three months. “The market seems to be unimpressed by GDP data and the rate cut because they probably anticipated more policy support,” said Margaret Yang, strategist at DailyFX. “The main concerns remain property and loan curbs, the ‘zero-Covid’ policy and a weak consumer market.” Benchmarks in Vietnam and South Korea were among the biggest decliners in the region. The Kospi lost more than 1% before a retail subscription for LG Energy Solution’s share float, the largest in the country’s history. Tencent and Meituan were among the biggest drags on the MSCI Asia Pacific Index. Asian stocks have outperformed their U.S. and European peers so far this year on cheaper valuations, as well as expectations that the worst of China’s tech clampdown has passed and confidence the region can quell omicron waves with timely social-distancing curbs. Tighter U.S. monetary policy is, however, weighing on regional shares and heavyweight tech stocks.

In FX, the Bloomberg Dollar Spot Index was little changed and the dollar was steady to weaker against all Group-of-10 peers apart from the yen; most currencies were confined in a narrow range with U.S. financial markets shut for a holiday. The euro inched up after testing the $1.14 handle and bund yields rose, led by the long end. Money markets today briefly wagered on 10-basis-points of ECB tightening as soon as September, the first time a move that month has been seen since before the omicron coronavirus variant roiled markets. The Canadian dollar and the Norwegian krone rose as Brent oil traded near the highest intraday level since 2014; the market tightened amid concerns about the impact of omicron eased. Norway’s exports surged to a record last year, helped by higher demand for fossil fuels, fish and metals. The pound was steady, with market focus on labor market and inflation data due later this week. Gilts yields rose by 3-4bps across the curve. The Bank of England is likely to hike its key rate at its next meeting, according to the median of a poll of economists. The yen weakened from the strongest in a month after hawkish comments from Fed officials on Friday spurred buying back of dollars; bonds stayed in a narrow range before a BOJ policy decision Tuesday. Overnight volatility in the yen remains subdued even amid speculation the Bank of Japan could change its view on price risks for the first time since 2014 when it sets policy on Tuesday.

In rates, Bunds and gilt curves bear steepen; gilts 1-2bps cheaper to bunds across the curve. Peripheral spreads tighten with 5y Italy outperforming. Money markets briefly price in 10bps of tightening by September before fading. Cash USTs stay closed for U.S. holiday but futures suggest the 10Y yield is currrently around 1.82% (see chart above).

In commodities, WTI back off Asia’s best levels to trade near $84, Brent is flat near $86. Spot gold drifts around the middle of Friday’s range close to $1,821/oz. Most base metals are in the red with LME nickel and copper underperforming.

There is nothing on the US economic calendar as the US is closed for MLK Day.

Top Overnight News from Bloomberg

  • China’s central bank cut its key interest rate for the first time in almost two years to help bolster an economy that’s lost momentum because of a property slump and repeated virus outbreaks
  • China’s population crisis continued to worsen in 2021, with the latest birth figures again sliding despite government efforts to encourage families to have more children
  • Boris Johnson faces another bruising week, with his future as U.K. prime minister in the balance amid a furious public backlash over rule-breaking parties at his Downing Street office
  • Governor Haruhiko Kuroda starts his last full year at the helm of Bank of Japan amid hints of public discontent over rising prices that could shape the direction of the central bank after he leaves or even as soon as coming months
  • Emerging-market central banks were the first in the world to raise interest rates from their pandemic lows last year. That proactive tightening is starting to pay off big time in boosting returns from their local bonds
  • As U.S. President Joe Biden’s administration looks to deter Russia from invading Ukraine, doubts are being raised about Germany’s readiness to confront President Vladimir Putin. When Foreign Minister Annalena Baerbock travels to Russia this week, her task will be to demonstrate that any questions over the new Berlin government’s resolve are misplaced

A more detailed look at global markets courtesy of Newqsuawk

Major bourses in Europe have kicked off the week mostly positive (Euro Stoxx 50 +0.5%; Stoxx 600 +0.4%) following a similar handover from the APAC session, which derived some support from Wall Street’s recovery on Friday – with US cash markets closed today for Martin Luther King Day. US futures see a holiday-shortened session but trade with little conviction in early European hours and within narrow parameters, albeit off the worst levels printed overnight. Back to Europe, a divergence is evident between the EUR-bourses (namely the AEX) and the non-EUR indices amid one main factor: Monday M&A which saw GSK (+4.7%) rejecting Unilever’s (-6.8%) GBP 50bln bid for GSK’s Consumer Health unit, with some reports suggesting the latter could up the offer to some GBP 60bln. This in turn jolted the Healthcare sector at the open (GSK accounts for around 9%) whilst the Personal and Household Goods sector is simultaneously pressured (Unilever accounts for around 13.5%) – thus underpinning the FTSE 100 (+0.7%) and the SMI (+0.6%) while the AEX (-0.6%) sits as the regional laggard. Delving deeper into the sectors, Basic Resources resides as one of the top performers as base metals are buoyed by China topping GDP growth expectations. Autos and Oil & Gas sit towards the bottom, with the latter seeing oil prices wane off best levels throughout the morning. In terms of individual movers, Credit Suisse (-1.2%) is weighed on after Chairman Antonio Horta-Osorio resigned with immediate effect after an internal company probe found he had broken the UK's Covid-19 quarantine rules in July. Darktrace (-4.5%) is lower as short-seller ShadowFall criticised the Co's performance, accounting and culture. ShadowFall confirmed that it had placed a bet against Darktrace in October, although the size was not disclosed. Siltronic (-7.0%) slumps as key requirements are still outstanding with regards to Germany's approval of the Co's sale to Taiwan's GlobalWafers. EDF (-2.1%) feels no reprieve as it cut output at its 1.3GW French oil and gas plant amid strikes, whilst the firm was also downgraded at HSBC. Looking at analyst commentary, Credit Suisse said value stocks usually see outperformance as yields rise, and the bank remains overweight Europe, UK and Japan. From a sectorial standpoint, Credit Suisse remains overweight on Financials, Mining, and Construction Materials, whilst the bank suggests it is too early to add tech. The bank suggests that yields in the 2-2.5% region will pose problems for equities as earnings, growth, fund flows and corporate purchases will be impacted.

In FX, the Dollar is waning again and the index is only just holding above 95.000 within a 95.291-035 band by virtue of upside in Usd/Jpy amidst firmer US Treasury yields and a steeper curve in wake of more hawkish Fed rhetoric via Williams as the last official speaker before the pre-January FOMC blackout. Meanwhile, the Yen has failed to glean full benefit from upbeat Japanese data in the form of machinery orders on the eve of the BoJ amidst reports that Tokyo and surrounding areas could be on the brink of entering quasi-emergency status due to the ongoing spread of COVID. However, the headline pair faces resistance above 114.50 via a Fib retracement level (114.58 representing 38.2% of the retreat from 116.35 to 113.48 this month) and 21 DMA (114.86), while nearest support is at the 50 DMA (114.27) and not far from decent option expiry interest (1 bn at 114.20). Note, thinner than average volumes, even for a Monday given MLK Day in the US.

  • CAD/NZD/CHF/EUR/AUD/GBP - While the Yen lags and Greenback flags, firm crude prices are underpinning the Loonie ahead of Canadian manufacturing sales and the BoC’s Business Outlook Survey that will be eyed for any early signs of adverse impact from the Omicron outbreak. Usd/Cad is currently towards the base of a 1.2508-57 range, while Nzd/Usd and Aud/Usd are hovering on 0.6800 and 0.7200 respective handles, but the Kiwi is marginally outperforming the Aussie against the backdrop of weakness in metals and mixed Chinese data. Aud/Nzd has been mostly a fraction under 1.0600 awaiting NZIER consumer sentiment in advance of electronic card retail sales, Aussie jobs and NZ manufacturing PMI later in the week. Elsewhere, the Franc has rebounded from sub-0.9150 and is firmer against the Euro between 1.0445-28 parameters even though weekly Swiss sight deposits indicate more SNB intervention, while Eur/Usd is contained within 1.1400-34 bounds and Cable is meandering from 1.3662-90 in the run up to a trio of top tier UK releases, including employment and earnings, inflation and retail sales.
  • SCANDI/EM - The Nok and Sek are pivoting 10.0000 and 10.3000 vs the Eur without too much reaction to Norway's trade surplus widening significantly to Nok 100+ bn, or Sweden’s mini budget showing Sek 18 bn set aside for pandemic-related measures, but the Cnh and Cny are both maintaining momentum around 6.3500 against the Usd following the aforementioned contrasting Chinese macro releases whereby GDP and IP beat consensus, but retail sales missed, plusPBoC easing via 10 bp reductions in the 1 year MLF and 7 day reverse repo. Conversely, the Rub continues to suffer from geopolitical and diplomatic angst as NATO pledges to reinforce Eastern members of the organisation if Russia decides to attack Ukraine.

In commodities, WTI and Brent front-month futures trade with no conviction but hold onto Friday’s gains, whilst overnight price action saw the latter reach prices last seen in 2014. The complex is underpinned by the mild upside bias across stocks, coupled with reopening vibes, geopolitical risk premia and the inability for some OPEC producers to ramp up output. To elaborate, weekend news flow regarding COVID was more sanguine from Europe, with nations set to ease COVID rules, albeit China’s Beijing city moves the other way amid its zero-COVID policy ahead of the winter Olympics. Geopolitical updates have been abundant, with the Russia/Ukraine situation tensions still heightened, while North Korea launched more projectiles. Further, Emirates News Agency noted three oil tanker explosions in the Al-Musaffah area in Abu Dhabi – potentially via drones emanating from Yemeni Houthis. Finally, reports via Argus Media on Friday suggested "The 19 Opec+ countries participating in the production restraint deal hiked their collective output by just 300k BPD in December, according to Argus' survey.”, suggesting the producers were around 650k BPD below their targets. WTI and Brent remain not far off the USD 84/bbl and USD 86/bbl marks respectively, with eyes on any further measures implemented by large oil consumers (such as the US and China) to reign in prices and avoid a larger knock-on effect on inflation. Elsewhere, spot gold is uneventful and trades around USD 1,820/oz mark – under the USD 1,830/oz resistance zone and above the 21 DMA at USD 1,802/oz. LME copper meanwhile was on a firmer footing following the Chinese GDP metrics overnight but has given up its earlier gains in early European hours with prices inching back towards USD 9,500/t.

DB's Jim Reid concludes the overnight wrap

Hope you had a good weekend. Fog and a very bad back stopped me golfing and I went swimming with the family instead. Two 12 year old boys clattered into me in the pool as they were involved in a horrendously aggressive play fight. I was furious as I got a good whack, and was about to give the man looking after them a piece of my mind, when I realised they were identical twins. My anger immediately turned to sympathy and when the Dad came over to apologise I said that I fully understood. Mine are only 4 and they wrestle, punch, slap, and trip each other up all the time. I thought they'd grow out of this but if these 12 years old boys were anything to go by I'm now very worried.

Talking of fights, it's becoming increasingly clear that 2022 is going to be a year where it's all about the battle between the Fed and financial conditions. After paying lip service to inflation for most of 2021, they have now got the bit between their teeth and in my opinion every meeting after March is live from a policy perspective. So if financial conditions don't tighten then we could have 7 hikes given how far behind the curve the Fed is on inflation. However a more likely outcome is that the Fed will be more measured as consistent rate hikes will probably lead to occasion market wobbles and gaps between the hikes. We will see. The other thing to look out for is a potential 50bps hike along the way and even as the opening gambit in March. This might feel fanciful but remember that since June, the pricing of various Fed Funds and taper/QT landmarks have repeatedly gone from zero to probable in relatively short order.

Our head of global economics Peter Hooper published a "What's in the tails?" piece last night looking at how there is an increasing risk that the Fed may want to move more quickly to neutral and even toward a restrictive monetary policy stance. He outlines what scenarios would need to happen for such an outcome. So while the team keep their 4 rate hikes and QT central view, they are acknowledging the upside risks to this. See the piece here.

After a late and notably bond sell off on Friday, that helped 10yr Treasury yields to end the week at fresh 2-year highs, markets will get some breathing space today with a US holiday and a Fed that are in their blackout period ahead of next week's FOMC.

 

The week has kicked off with China's monthly data dump but the PBOC upstaged this by surprisingly cutting rates on its medium term loans ahead of the GDP release. In the first move since April 2020, the PBOC lowered its one-year medium term lending facility (MLF) rate by 10bps to 2.85% from 2.95% and slashed the seven-day repurchase rate to 2.1% from 2.2%. Additionally, the central bank injected 700 bn yuan ($110 bn) worth of liquidity via the MLF and added 100 billion yuan of liquidity via reverse repos. Separately, data showed Q4 GDP expanded +4.0% y/y beating Bloomberg forecast of 3.3%. However, the rise was more muted in the last three months (+4.9%) as a real estate downturn combined with strict Covid-19 curbs hit activity.

Other economic data showed that industrial production in China jumped by +4.3% in December from a year ago surpassing market expectations of a +3.7% growth. In addition to this, Fixed asset investment for 2021 advanced by +4.9%, topping market expectations for +4.8% rise. However, retail sales missed expectations (+3.8%) with only a +1.7% gain in December from a year earlier, its slowest increase since August 2020.

In early trade today, markets across Asia are off to a cautious start. Japan's Nikkei (+0.84%) is inching higher, recouping losses from the previous two sessions, with the CSI (+0.86%) and Shanghai Composite (+0.59%) trading in positive territory. Elsewhere, the Kospi (-1.34%) and Hang Seng (-0.59%) are losing ground. In other data news, Japan's core machinery orders grew +3.4% in November (+3.8% last month), rising for the second straight month, suggesting a decent private demand-led recovery in the world's third-biggest economy.

In terms of the rest of the week, earnings season will begin to gather some momentum, with 39 S&P 500 companies reporting. Elsewhere the Bank of Japan will be making its latest monetary policy decision tomorrow which is unlikely to see much change now but reputable press reports are suggesting they are ready to become more hawkish in the coming months with a credible Reuters story late last week suggested they are prepared to raise rates before inflation reaches 2%. This is still someway off but if the BoJ can become more hawkish then that says something about the global direction of travel for monetary policy.

Otherwise on the data front, there’ll be further developments on inflation as the UK releases its CPI print for December, with our economist expecting a further rise to +5.3% on a year-on-year basis. If realised, that would be the highest CPI print since March 1992. That’ll also be the last CPI reading ahead of the BoE’s next policy decision on February 3, where our economist is expecting a further 25 basis point hike.

In terms of more details on earnings season, with 39 S&P 500 companies reporting ahead of the two peak weeks, the highlights are Goldman Sachs and BNY Mellon tomorrow, before we hear from UnitedHealth Group, Bank of America, Procter & Gamble, ASML, Morgan Stanley, Charles Schwab, US Bancorp and United Airlines on Wednesday. Finally on Thursday, there’s reports from Netflix, Union Pacific and American Airlines Group. For those interested, DB's asset allocation team have put out a Q4 earnings preview (link here).

Recapping last week now, global sovereign yields drifted lower most of the week after ripping higher to start the year. However a sizable selloff on Friday took us to fresh 2 year yield highs. Equity markets ended the week lower but enjoyed some respite from the otherwise torrid start to the year.

Diving in, there was a chorus of Fed speakers this week ahead of their January FOMC communications blackout. Foremost among them, Chair Powell and Governor Brainard testified before the Senate Banking Committee as part of their hearings for respective (re)nominations as Chair and Vice Chair of the Fed. They set the tone that was broadly echoed by other Governors and regional Presidents over the week: the first rate hike was likely coming in March (in line with our US economists expectations), and QT would be employed sometime in 2022 to fight inflation. We ended the week with a 97% probability of a March hike, the highest this cycle, and 2 full hikes priced by the June FOMC. Our economists are expecting 4 rate hikes this year, in addition to QT beginning, and the market is currently pricing around 3.8 hikes through the year.

The growing consensus around earlier Fed tightening lifted 2yr treasury yields +10.5bps this week, most of it via a +7.4bps increase on Friday. Farther out the curve, 10yr treasury yields were a bit calmer compared to the week before, ending the week +2.2bps higher (+8.0bps Friday) after drifting lower most of the week before a sharp end week sell-off. In Europe, 10yr bunds and gilts fell a modest -0.3bps (+4.4bps Friday) and -2.8bps (+4.5bps Friday) respectively but closed before the last leg of the US bond sell off.

The S&P 500 managed its first consecutive days of increases in 2022 last week, but still fell -0.30% on the week (+0.08% Friday), bringing it -2.17% lower to start the year. European equities were not spared, with the STOXX 600 falling -1.05% (-1.01% Friday), the DAX down -0.40% (-0.93% Friday) and the CAC lower by -1.06% (-0.81% Friday). Higher real 10yr treasury yields have been a big culprit so far, having increased an additional +7.2bps this week (+7.6bps Friday) to -0.70%, their highest level since April. However they were at -0.88bp late on Wednesday so a pretty choppy week. Risk sentiment was also likely impacted by geopolitics. In particular, the talks between US, its NATO allies, and Russia proving less-than-optimal.

Crude oil had another strong week, with Brent increasing +5.77% (+2.41% Friday) and WTI up +6.81% (+2.60% Friday). Oil is once again making a strong bid to be the best performing asset in 2022, with both Brent and WTI up over +10% to start the year. US earnings season kicked off with releases from major financials, JPM, Wells Fargo, and Blackrock. The two banks beat sales and revenue expectations but had below consensus revenues stemming from FICC trading. Blackrock posted higher earnings but lower sales per share than expected.

Turning to data, despite shrinking in Q4, German GDP grew 2.7 percent over 2021, driven by strong government spending, net exports, and investment. Private consumption was stagnant as real disposable income fell with rising prices.

US CPI reached 7.0 percent year-over-year in December, in line with expectations and the highest level since 1982. Core CPI increased 5.5 percent, year-over-year, slightly higher than consensus expectations. Price increases were broad-based across components. US retail sales declined -1.9 percent month-over-month in December, well below consensus expectations, perhaps a reflection of US consumers bringing holiday shopping forward to avoid any supply chain-driven delays.

Tyler Durden Mon, 01/17/2022 - 08:32

Read More

Continue Reading

Government

Family Of College Student Who Died From COVID-19 Vaccine Sues Biden Administration

Family Of College Student Who Died From COVID-19 Vaccine Sues Biden Administration

Authored by Zachary Stieber via The Epoch Times (emphasis…

Published

on

Family Of College Student Who Died From COVID-19 Vaccine Sues Biden Administration

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

The family of a college student who died from heart inflammation caused by Pfizer’s COVID-19 vaccine has sued President Joe Biden’s administration, alleging officials engaged in “willful misconduct.”

George Watts Jr. in a file image. (Courtesy of the Watts family)

U.S. Department of Defense (DOD) officials wrongly promoted COVID-19 vaccination by repeatedly claiming the available vaccines were “safe and effective,” relatives of George Watts Jr., the college student, said in the new lawsuit.

That promotion “duped millions of Americans, including Mr. Watts, into being DOD’s human subjects in its medical experiment, the largest in modern history,” the suit states.

The Public Readiness and Emergency Preparedness Act allows lawsuits against certain people if they have engaged in “willful misconduct” and if that misconduct caused death or serious injury.

COVID-19 vaccines are covered by the act due to a declaration entered during the Trump administration in 2020 after COVID-19 began circulating.

DOD’s conduct and the harm caused as alleged within the four corners of the lawsuit speaks for itself,” Ray Flores, a lawyer representing the Watts family, told The Epoch Times via email. “I have no further comment other than to say: My only duty is to advocate for my client. If the DOD conveys a settlement offer, I will see that it’s considered.”

The suit was filed in U.S. court in Washington.

The Pentagon and the Department of Justice did not respond to requests for comment.

Watts Suddenly Died

Watts was a student at Corning Community College when the school mandated COVID-19 vaccination for in-person classes in 2021. He received one Pfizer dose on Aug. 27, 2021, and a second dose approximately three weeks later.

Watts soon began experiencing a range of symptoms, including tingling in the feet, pain in the heels, numbness in the hands and fingers, blood in his sperm and urine, and sinus pressure, according to family members and health records.

Watts went to the Robert Packer Hospital emergency room on Oct. 12, 2021, due to the symptoms. X-rays showed clear lungs and a normal heart outline.

Watts was sent home with suggestions to follow up with specialists but returned to the emergency room on Oct. 19, 2021, with worsening symptoms despite a week of the antibiotic Augmentin. He was diagnosed with sinusitis and bronchitis.

While speaking to his mother at home on Oct. 27, 2021, Watts suddenly collapsed. Emergency medical personnel rushed to the home but found him unresponsive. He was rushed to the same hospital in an ambulance. He was pronounced deceased at age 24.

According to a doctor at the hospital, citing hospital records and family members, Watts had no past medical history on file that would explain his sudden death, with no known history of substance abuse or obvious signs of substance abuse. His mother described her son as a “healthy young male.”

Dr. Robert Stoppacher, a pathologist who performed an autopsy on the body, said that the death was due to “COVID-19 vaccine-related myocarditis.” The death certificate listed no other causes. A COVID-19 test returned negative. Dr. Sanjay Verma, based in California, reviewed the documents in the Watts case and said that he believed the death was caused by the COVID-19 vaccination.

Pfizer did not respond to a request for comment.

Watts Took Vaccine Under Pressure

The community college mandate included a 35-day grace period following approval by the U.S. Food and Drug Administration (FDA) of a COVID-19 vaccine.

The Moderna, Pfizer, and Johnson & Johnson vaccines were given emergency use authorization early in the pandemic. The FDA approved the Pfizer shot on Aug. 23, 2021. It was the first COVID-19 vaccine approval. But doses of the approved version of the shot, branded Comirnaty, were not available for months after the approval.

Read more here...

Tyler Durden Fri, 06/02/2023 - 23:00

Read More

Continue Reading

International

US Sent Billions in Funding to China, Russia For Cat Experiments, Wuhan Lab Research: Ernst

US Sent Billions in Funding to China, Russia For Cat Experiments, Wuhan Lab Research: Ernst

Authored by Mark Tapscott via The Epoch Times…

Published

on

US Sent Billions in Funding to China, Russia For Cat Experiments, Wuhan Lab Research: Ernst

Authored by Mark Tapscott via The Epoch Times (emphasis ours),

Hundreds of millions of U.S. tax dollars went to recipients in China and Russia in recent years without being properly tracked by the federal government, including a grant that enabled a state-run Russian lab to test cats on treadmills, according to Sen. Joni Ernst (R-Iowa).

Sen. Joni Ernst (R-Iowa) speaks at a Senate Republican news conference in the U.S. Capitol on March 9, 2022. (Anna Moneymaker/Getty Images)

Ernst and her staff investigators, working with auditors at the Government Accountability Office (GAO) and the Congressional Research Service, as well as two nonprofit Washington watchdogs—Open The Books (OTB) and the White Coat Waste Project (WCWP)—discovered dozens of other grants that weren’t counted on the federal government’s USASpending.gov internet database.

While the total value of the uncounted grants found by the Ernst team is $1.3 billion, that amount is just the tip of the iceberg, the GAO reported.

Among the newly discovered grants is $4.2 million to China’s infamous Wuhan Institute of Virology (WIV) “to conduct dangerous experiments on bat coronaviruses and transgenic mice,” according to a May 31 Ernst statement provided to The Epoch Times.

The $4.2 million exposed by Ernst is in addition to previously reported funding to the WIV for extensive gain-of-function research by Chinese scientists, much of it funded in whole or part prior to the COVID-19 pandemic by National Institutes for Health (NIH) grants channeled through the EcoHealth Alliance medical research nonprofit.

The NIH has awarded seven grants totaling more than $4.1 million to EcoHealth to study various aspects of SARS, MERS, and other coronavirus diseases.

Buying Chinese Puppy Parts

As part of another U.S.-funded grant, hearts and other organs from 425 dogs in China were purchased for medical research.

These countryside dogs in China are part of the farmer’s household; they were mainly used for guarding. Their diet includes boiled rice, discarded raw food animal tissues, and whatever dogs can forage. These dogs were sold for food,” an NIH study uncovered by the Ernst researchers reads.

Other previously unreported grants exposed by the Ernst team include $1.6 million to Chinese companies from the federal government’s National School Lunch Program and $4.7 million for health insurance from a Russian company that was sanctioned by the United States in 2022 as a result of the invasion of Ukraine.

“It’s gravely concerning that Washington’s reckless spending has reached the point where nobody really knows where all tax dollars are going,” Ernst separately told The Epoch Times. “But I have the receipts, and I’m shining a light on this, so bureaucrats can no longer cover up their tracks, and taxpayers can know exactly what their hard-earned dollars are funding.”

The problem is that federal officials don’t rigorously track sub-awards made by initial grant recipients, according to the Iowa Republican. Such sub-awards are covered by a multitude of federal regulations that stipulate many conditions to ensure that the tax dollars are appropriately spent.

The GAO said in an April report that “limitations in sub-award data is a government-wide issue and not unique to U.S. funding to entities in China.”

GAO is currently examining the state of federal government-wide sub-award data as part of a separate review,” the report reads.

Peter Daszak, right, the president of the EcoHealth Alliance, is seen in Wuhan, China, on Feb. 3, 2021. (Hector Retamal/AFP via Getty Images)

The Eco-Health sub-awards to WIV illustrate the problem.

“Despite being required by law to make these receipts available to the public on the USAspending.gov website, EcoHealth tried to cover its tracks by intentionally not disclosing the amounts of taxpayer money being paid to WIV, which went unnoticed for years,” Ernst said in the statement.

“I was able to determine that more than $490 million of taxpayer money was paid to organizations in China [in] the last five years. That’s ten times more than GAO’s estimate! Over $870 million was paid to entities in Russia during the same period!

Together that adds up to more than $1.3 billion paid to our adversaries. But again, these numbers still do not represent the total dollar amounts paid to institutions in China or Russia since those numbers are not tracked and the information that is being collected is incomplete.”

Adam Andrzejewski, founder and chairman of OTB, told The Epoch Times, “When following the money at the state and local level, the real corruption exists in the subcontractor payments. At the federal level, the existing system doesn’t even track many of those recipients.

“Without better reporting, agencies and appropriators don’t truly understand how tax dollars were used. We now know that taxpayer dollars are traded further downstream than originally realized with third- and fourth-tier recipients. These transactions need scrutiny. Requiring recipients to account for where and how they actually spend each dollar creates a record far better than agencies are capable of generating.”

Read more here...

Tyler Durden Fri, 06/02/2023 - 19:40

Read More

Continue Reading

Government

OraSure Technologies’ CFO Makes Bold Insider Purchase, Reigniting Investor Confidence

Executive Kenneth McGrath’s $500,000 buy read as promising signal about future for diagnostic test developer OraSure Technologies (NASDAQ:OSUR) saw…

Published

on

By

Executive Kenneth McGrath’s $500,000 buy read as promising signal about future for diagnostic test developer

OraSure Technologies (NASDAQ:OSUR) saw a stock price re-rate on Thursday, climbing 11% after investors became aware of its CFO Kenneth McGrath buying shares in the diagnostic test developer.  This latest rally in OSUR stock, gives traders and investors hope that the strong momentum from the beginning of 2023 might return.

OSUR shares had mounted an impressive 54% rally for 2023 through to May 10, when the first-quarter results update spooked investors. 

The CFO’s trade was initially spotted on Fintel’s Insider Trading Tracker following the filing with the Securities and Exchange Commission.

Big Holdings Boost

In the Form 4 filing, McGrath, who assumed CFO duties in August 2022, disclosed buying 100,000 shares on May 30 in the approved trading window that was open post results.

McGrath on average paid $4.93 per share, giving the total transaction a value just shy of $500,000 and boosted his total share count ownership to 285,512 shares.

The chart below from the insider trading and analysis report for OSUR shows the share price performance and profit made from company officers in previous transactions:

OraSure Technologies

Prior to joining OraSure, McGrath had an impressive eight-year tenure at Quest Diagnostics (NYSE:DGX), where he rose to the position of VP of Finance before departing. This is the first time that the CFO has bought stock in the company since August 2022. It is also worth noting that the purchase followed strong Q1 financial results, which exceeded Street forecasts.

Revenue Doubles

In its recently published Q1 update, OraSure Technologies told investors that it generated a whopping 129% increase in revenue to $155 million, surpassing analyst expectations of around $123 million. 

Notably, the revenue growth was driven primarily by the success of OraSure’s COVID-19 products, which accounted for $118.4 million in revenue for the quarter and grew 282% over the previous year.

The surge in revenue for this product was largely driven by the federal government’s school testing program, which led to record test volumes. However, it is important to note that demand for InteliSwab is expected to decline in Q2 2023, prompting OraSure to scale down its COVID-19 production operations. As part of its broader strategy to consolidate manufacturing, the company plans to close an overseas production facility.

While the COVID-19 products division has been instrumental in OraSure’s recent success, its core business delivered stable flat sales of $36.6 million during the quarter. 

In terms of net income, OraSure achieved an impressive result of $27.2 million, or $0.37 per share, in Q1, marking a significant improvement compared to the loss of $19.9 million, or a loss of $0.28 per share, in the same period last year. This result exceeded consensus forecasts of $0.16 per share. As of the end of the quarter, the company held $112.4 million in cash and cash equivalents.

Looking ahead to Q2, OraSure has provided revenue guidance in the range of $62 to $67 million, reflecting the lower order activity from the US government with $25 to $30 million expected sales for InteliSwab. The declining Covid related sales have been a core driver of the share price weakness in recent weeks.

While sales are likely to fall in the coming quarters, one positive for the company is its low debt balance during this period of rising cash rates. The chart below from Fintels financial metrics and ratios page for OSUR shows the cash flow performance of the business over the last five years.

OraSure Technologies

Analyst Opinions

Stephen’s analyst Jacob Johnson thinks that outside of Covid, OSUR continues to execute on several cost and partnership initiatives which he believes appears to be bearing fruit. Johnson pointed out that three partnerships were signed during the quarter.

The analyst thinks that the ex-Covid growth story will be the new focus for investors from now on. The brokerage maintained its ‘equal-weight’ recommendation and $6.50 target price on the stock, matching Fintel’s consensus target price, suggesting OSUR stock could rise a further 29% in the next 12 months. 

The post OraSure Technologies’ CFO Makes Bold Insider Purchase, Reigniting Investor Confidence appeared first on Fintel.

Read More

Continue Reading

Trending